BRANFORD, Conn., May 7 /PRNewswire-FirstCall/ -- Neurogen Corporation
(Nasdaq: NRGN), a drug discovery and development company, announced today that
President and CEO William H. Koster, Ph.D., will present during a panel
discussion at the SunTrust Robinson Humphrey Therapeutic Conference on May 11,
2004 at 3:15 p.m. EDT. Also participating will be Executive Vice President,
Chief Business Officer Stephen R. Davis, ESQ. and Senior Vice President of
Clinical Research and Development James V. Cassella, Ph.D. The question and
answer format will be led by SunTrust Robinson Humphrey biotechnology analyst,
David Witzke, Ph.D.
The Therapeutics Conference is designed to give investors the chance to
meet face-to-face with the management of participating companies in an
informal Q & A setting.
The panel will be webcast live from the Le Parker Meridien Hotel in New
York City and may be accessed through www.suntrustrh.com or through the
investor relations section of the Company's web site: www.neurogen.com.
About Neurogen Corporation
Neurogen Corporation targets new small molecule drugs to improve the lives
of patients suffering from disorders with significant unmet medical need,
currently: inflammation, pain, insomnia, depression, and obesity. Neurogen
continues to generate a portfolio of compelling new drug candidates through
its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in
cellular functional assays, and its depth in medicinal chemistry. The Company
conducts its drug research and clinical development independently or, on
selected programs, collaborates with world-class pharmaceutical companies to
access complementary expertise.
SOURCE Neurogen Corporation
CONTACT: Elaine Grimsell Beckwith of Neurogen Corp., +1-203-315-4615,
Web site: http://www.neurogen.com